Phase II Trial of Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer (With Trastuzumab in HER2 Positive Patients).

Trial Profile

Phase II Trial of Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer (With Trastuzumab in HER2 Positive Patients).

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2013

At a glance

  • Drugs Cyclophosphamide (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
  • Indications Early breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 02 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 May 2011 Actual end date (September 2010) added as reported by ClinicalTrials.gov.
    • 14 Oct 2008 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top